Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on 28 April 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy's readiness to ensure patient access following approval.
In Canada, Dr. Reddy's Semaglutide Injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in a pre-filled pen, available in 2 mg/pen and 4 mg/pen strengths, each delivering Semaglutide at a concentration of 1.34 mg/ml. The 2 mg/pen is designed to deliver 0.25 mg or 0.5 mg doses, while the 4 mg/pen delivers 1 mg doses per injection.
Securities in F&O Ban:
Steel Authority of India are banned from F&O trading on 13 May 2026.
Result Today:
Balaji Amines, The Bombay Burmah Trading Corporation, Bharti Airtel, Bharti Hexacom, CARE Ratings, Cipla, Crompton Greaves Consumer Electricals, DCM Shriram, DLF, eClerx Services, GlaxoSmithKline Pharmaceuticals, Hindustan Petroleum Corporation, Inventurus Knowledge Solutions, Interarch Building Solutions, JSW Dulux, Kaynes Technology India, Kirloskar Brothers, LIC Housing Finance, Man Infraconstruction, Metropolis Healthcare, NLC India, Oil Indi, Onesource Specialty Pharma, Paras Defence and Space Technologies, Power Finance Corporation, Quality Power Electrical Equipments, Redington, Sagar Cements, Sharda Cropchem, Signatureglobal (India), SKF India, Suven Life Sciences, Tourism Finance Corporation of India, Tube Investments of India, Tata Motors, TVS Holdings, TVS Motor Company, Zaggle Prepaid Ocean Services and ZF Commercial Vehicle Control Systems India
Stocks to Watch:
Dr. Reddy's Laboratories reported an 86.14% decline in consolidated net profit to Rs 220.9 crore on an 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 compared with Q4 FY25.
Berger Paints India reported a 27.9% rise in consolidated net profit to Rs 335 crore from Rs 262 crore. Revenue increased 6.1% to Rs 2,868 crore from Rs 2,704 crore.
Dixon Technologies (India) reported a 35.91% decline in consolidated net profit to Rs 297.97 crore on a 2.12% increase in revenue from operations to Rs 10,510.51 crore in Q4 FY26 compared with Q4 FY25.
Neuland Laboratories reported a 665.1% jump in consolidated net profit to Rs 212.7 crore from Rs 27.8 crore. Revenue rose 134.8% to Rs 788.7 crore from Rs 335.8 crore.
Tata Power reported a 4.5% decline in consolidated net profit to Rs 996 crore from Rs 1,043 crore. Revenue fell 12.9% to Rs 14,900 crore from Rs 17,096 crore.
Torrent Power reported a 70% decline in consolidated net profit to Rs 318 crore from Rs 1,059 crore. Revenue slipped 0.8% to Rs 6,406 crore from Rs 6,456 crore.
Thomas Cook (India) reported a 40.1% decline in consolidated net profit to Rs 38.7 crore from Rs 64.6 crore. Revenue fell 10.1% to Rs 1,771 crore from Rs 1,969 crore.
Kalpataru reported a consolidated net profit of Rs 200 crore compared with Rs 14.1 crore a year ago. Revenue surged 183.7% to Rs 1,694 crore from Rs 597 crore.
Dr Reddys Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 1268.7, down 0.1% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.54% on the day, quoting at 23505.1. The Sensex is at 74897.31, up 0.45%.Dr Reddys Laboratories Ltd has gained around 4.18% in last one month.Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has increased around 6.93% in last one month and is currently quoting at 23840.9, up 0.63% on the day. The volume in the stock stood at 77.06 lakh shares today, compared to the daily average of 31.23 lakh shares in last one month.
The benchmark May futures contract for the stock is quoting at Rs 1269.7, up 0.13% on the day. Dr Reddys Laboratories Ltd jumped 3.99% in last one year as compared to a 4.71% slide in NIFTY and a 11.69% spurt in the Nifty Pharma index.
The PE of the stock is 22.85 based on TTM earnings ending December 25.
For the full year,net profit declined 25.80% to Rs 4196.00 crore in the year ended March 2026 as against Rs 5655.10 crore during the previous year ended March 2025. Sales rose 3.19% to Rs 33593.30 crore in the year ended March 2026 as against Rs 32553.50 crore during the previous year ended March 2025.
Excluding the one-time SSA, consolidated revenues were at Rs 7,970 crore in Q4FY26, a decline of 6.3% YoY and 8.7% QoQ and Rs 34,050 billion in FY26, a growth of 4.6% YoY.
Profit before tax (PBT) dropped 90.04% YoY to Rs 199.7 crore in Q4 FY26.
EBITDA slipped 60.37% to Rs 980.7 crore in Q4 FY26 compared with Rs 2,474.9 crore in Q4 FY25. EBITDA margin contracted to 13% in Q4 FY26 as against 29.1% in Q4 FY25. Excluding the SSA impact, EBITDA margin stood at 19.5% in Q4 FY26.
Revenue from global generics tumbled 13% YoY to Rs 6,580 crore during the quarter.
In Q4 FY26, revenue from North America declined 51% YoY to Rs 1,760 crore, Decline was largely due to lower Lenalidomide sales and the one-time SSA. Excluding this one-off, revenues for the segment recorded a 38% YoY decline and a 25% sequential decline in Q4 FY26.
Revenue from India jumped 20% YoY to Rs 1,570 crore in Q4 FY26, driven by revenues from new brand launches, including products from its innovation portfolio, price increases, higher volumes and contributions from recently acquired portfolios.
Revenue from Europe region increased 14% YoY to Rs 1,450 crore during the quarter, while revenue from emerging markets jumped 29% YoY to Rs 1,810 crore in Q4 FY26, aided by new launches across markets and higher volumes, further supported by favourable forex.
R&D Expenses stood at Rs 550 crore during the quarter, registering de-growth of 25% YoY, and accounted for 7.3% of revenue. The decline was mainly due to lower development spending in biosimilars following the completion of major investments related to Abatacept. The company said R&D spending continues to focus on complex generics, peptides and biosimilars. Q4FY26 was also impacted by charges related to certain discontinued CAR-T assets, while FY26 included the one-time new Labour Codes provision.
On full year basis, the company’s consolidate net profit tumbled 25.8% to Rs 4196 crore despite 3.24% jump in revenue from operations to Rs 33,700.2 crore in FY26 over FY25.
Co-Chairman & MD, G V Prasad said: 'Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact. We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimization. In parallel, we continue to build long-term franchises in biosimilars, consumer health and innovation to deliver sustainable value.”
Meanwhile, the company’s board recommended a final dividend of Rs 8 per equity share of face value of Rs 1 each for the financial year 2025-26. The record date for the dividend has been fixed as 10 July 2026.
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
The scrip shed 0.76% to settle at Rs 1,270.10 on the BSE.
OneSource Specialty Pharma announced that its partner Dr. Reddy's Laboratories has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.
The partnership is designed to ensure reliable and scalable commercial supply from OneSource's US-FDA approved flagship manufacturing facility in Bengaluru.
Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy's has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy's expertise in peptide development with OneSource's CDMO capabilities.”
Shree Ganesh Remedies Ltd rose 3.78% today to trade at Rs 535. The BSE Healthcare index is up 0.27% to quote at 43607.96. The index is up 4.13 % over last one month. Among the other constituents of the index, Themis Medicare Ltd increased 2.49% and Dr Reddys Laboratories Ltd added 2.31% on the day. The BSE Healthcare index went up 2.14 % over last one year compared to the 2.79% fall in benchmark SENSEX.
Shree Ganesh Remedies Ltd has added 11.02% over last one month compared to 4.13% gain in BSE Healthcare index and 5.15% rise in the SENSEX. On the BSE, 900 shares were traded in the counter so far compared with average daily volumes of 5550 shares in the past one month. The stock hit a record high of Rs 828 on 23 Apr 2025. The stock hit a 52-week low of Rs 381.1 on 27 Jan 2026.